Antibody‑Drug Conjugate Proves Active in Ovarian Cancer
The TROP2‑directed antibody‑drug conjugate DB‑1305/BNT325 demonstrated durable antitumor activity, achieving a 41.4% overall objective response rate in patients with previously treated ovarian cancer.
In a phase‑1/2a trial (NCT05438329) of 58 heavily pre‑treated ovarian cancer patients, DB‑1305/BNT325 achieved an overall objective response rate of 41.4%, with durable responses and a manageable safety profile.
These findings support further clinical development of a novel TROP2‑directed ADC as a new therapeutic option for patients with limited alternatives in platinum‑resistant ovarian cancer.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements